Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018 ; volume:195 ; number:2 ; day:22 ; month:7 ; year:2022 ; pages:171-180 ; date:9.2022
Breast cancer research and treatment ; 195, Heft 2 (22.7.2022), 171-180, 9.2022
- Urheber
-
Kaplan, Henry G.
Malmgren, Judith A.
Guo, Boya
Atwood, Mary K.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-022-06678-1
- URN
-
urn:nbn:de:101:1-2022112709362523597156
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kaplan, Henry G.
- Malmgren, Judith A.
- Guo, Boya
- Atwood, Mary K.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
How We Treat HER2-Positive Metastatic Breast Cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
How We Treat HER2-Positive Metastatic Breast Cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
How We Treat HER2-Positive Metastatic Breast Cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer